Ann Forslund
About Ann Forslund
Ann Forslund is the Scientific Director at Bristol Myers Squibb, with extensive experience in translational medicine, oncology, and biomarkers.
Title and Current Role
Ann Forslund is currently serving as the Scientific Director at Bristol Myers Squibb. Her role encompasses overseeing scientific research and strategies to advance the company's oncology pipeline. She plays a key role in guiding scientific teams, focusing on innovative approaches in cancer treatment.
Previous Roles in Oncology Research
Ann Forslund has held several significant positions within leading pharmaceutical companies. From 2018 to 2023, she served as Associate Director for Precision Medicine and Translational Research in Oncology at Bristol Myers Squibb in Princeton, New Jersey. Prior to this, she worked at Gilead Sciences from 2016 to 2018 as Research Scientist II in Translational Medicine and Biomarkers in Oncology in Greater Seattle Area. She also spent a year at Johnson & Johnson as Senior Scientist, Translational Research Hematological Malignancies in the United States (2015-2016), and six years in Belgium as Senior Scientist, Oncology Biomarkers (2009-2015).
Early Career and Research Experience
Ann Forslund's early career includes significant research roles. From 2008 to 2009, she worked at Einstein Healthcare Network as an Associate in the Department of Molecular Genetics. Between 2006 and 2008, she was an Associate Research Scientist at Columbia University. Her postdoctoral research fellowship at Memorial Sloan Kettering Cancer Center lasted from 2003 to 2006. She also served as a Research Scientist at Sahlgrenska University Hospital from 2001 to 2003.
Educational Background in Cancer Genomics and Research
Ann Forslund holds a Ph.D. in Cancer Genomics from Göteborgs universitet, completed between 1996 and 2001. She also pursued studies at the University of Regensburg (1994-1995) in Biology, Medicine; and German Language, achieving remarkable expertise in Cancer Research Tumor Immunology. Her foundational education includes a Master's degree in Biology from the University of Gothenburg (1989-1994). Additionally, she spent a year at The University of Georgia studying a mix of Biology, Medicine, and other diverse subjects (1992-1993).
Expertise in Translational Medicine and Oncology
Ann Forslund has extensive expertise in translational medicine, particularly focused on oncology and biomarkers. Her work spans both early and late-stage drug development projects, emphasizing personalized medicine. She has a robust background in immune-oncology and tyrosine kinase inhibitors (TKIs). Throughout her career, she has been actively involved in clinical trials and the development of new cancer therapies. Her specialization in molecular profiling of cancer assists in identifying specific biomarkers crucial for targeted therapies.